{"id":2994,"date":"2026-08-01T19:22:41","date_gmt":"2026-08-02T02:22:41","guid":{"rendered":"https:\/\/www.ultalabtests.com\/blog\/?p=2994"},"modified":"2026-08-07T14:33:07","modified_gmt":"2026-08-07T21:33:07","slug":"cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers","status":"publish","type":"post","link":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","title":{"rendered":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Cancer blood tests<\/strong> include routine blood counts and chemistry tests, selected protein tumor markers, and specialized genomic assays. They may reveal blood-cell or organ-function changes, support a diagnosis alongside imaging and pathology, establish a pretreatment baseline, monitor treatment safety or response, and help watch for recurrence. <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> may be considered for prostate-cancer screening after an informed discussion; most markers\u2014including <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>\u2014are not broad stand-alone screening tests. Benign conditions can raise them, some cancers do not produce them, and a normal result does not rule out cancer. Persistent symptoms, a markedly abnormal result, or a concerning examination or imaging finding requires prompt professional evaluation, often including imaging, endoscopy, biopsy, and specialist interpretation.<sup><a href=\"#ref-1\">1<\/a>\u2013<a href=\"#ref-5\">5<\/a><\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Part of the Ulta Lab Tests Knowledge Center<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Start with <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/complete-guide-to-lab-tests-and-blood-work\/\">the complete guide to lab tests and blood work<\/a> for an overview of specimens, panels, screening, diagnostic support, and monitoring. For result interpretation, use <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/how-to-read-lab-results\/\">how to read and understand your lab results<\/a>. To understand ordering, preparation, collection, and follow-up, review <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/direct-access-lab-testing\/\">how direct-access lab testing works<\/a>.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/blood-disorders\/cbc-anemia-blood-tests\/\">CBC, anemia, iron, and blood-cell testing<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/mens-health\/all-mens-health\/mens-health-blood-tests\/\">men\u2019s hormone, testosterone, sexual, and prostate testing<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/liver-function-tests\/\">liver function and metabolic liver testing<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/inflammation\/inflammation-autoimmune-blood-tests\/\">inflammation and autoimmune blood testing<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/blog\/genomic-testing\/genetic-genomic-testing\/\">genetic and genomic testing<\/a><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Key Facts About Cancer Blood Tests<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Core test or test group<\/th><th>Common specimen<\/th><th>Fasting or timing need<\/th><th>Primary purpose<\/th><th>Common use status<\/th><th>Major limitation<\/th><\/tr><\/thead><tbody><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with differential<\/a><\/th><td>Blood<\/td><td>Usually no fasting; timing may matter during treatment<\/td><td>Evaluate red cells, white cells, and platelets; establish baseline; monitor marrow effects and treatment safety<\/td><td>Common or first-line; monitoring<\/td><td>Abnormal patterns are nonspecific, and many cancers cause no <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> change<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> and organ-function testing<\/th><td>Blood<\/td><td>Fasting may be requested when combined with glucose or other tests<\/td><td>Assess liver, kidney, electrolyte, protein, calcium, and glucose patterns; monitor treatment safety<\/td><td>Common or first-line; monitoring<\/td><td>Does not locate or diagnose a tumor<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a><\/th><td>Blood<\/td><td>Recent prostate procedures, infection, ejaculation, and some medicines may affect interpretation<\/td><td>Shared-decision screening, symptom evaluation, follow-up, and monitoring of known prostate cancer<\/td><td>Risk-based or targeted; monitoring<\/td><td>Not cancer-specific; no single <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> value proves or excludes cancer<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><\/th><td>Blood<\/td><td>Menstrual cycle, pregnancy, and pelvic or liver conditions may affect the result<\/td><td>Primarily monitoring ovarian cancer; selected evaluation of a pelvic mass<\/td><td>Targeted; monitoring<\/td><td>Not recommended for routine screening of average-risk asymptomatic people<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/th><td>Blood<\/td><td>Smoking status and liver, digestive, or inflammatory conditions matter<\/td><td>Baseline, treatment-response, and recurrence monitoring\u2014especially in colorectal cancer<\/td><td>Monitoring<\/td><td>Not a colorectal-cancer screening or diagnostic test by itself<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a><\/th><td>Blood<\/td><td>Pregnancy and chronic liver disease materially affect interpretation<\/td><td>Selected liver and germ-cell tumor evaluation and monitoring<\/td><td>Targeted; monitoring<\/td><td>Can be elevated without cancer and can remain normal with cancer<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a><\/th><td>Blood; <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a> may also be measured in urine<\/td><td>Pregnancy, biliary obstruction, pancreatitis, and test context are critical<\/td><td>Selected gastrointestinal, pancreaticobiliary, trophoblastic, or germ-cell tumor contexts<\/td><td>Targeted; monitoring<\/td><td>Neither is a universal screening test; some people do not produce <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a><\/th><td>Blood; related urine testing may be used<\/td><td>Usually no fasting; kidney function affects free-light-chain interpretation<\/td><td>Evaluate suspected monoclonal protein or plasma-cell disorder; monitor known disease<\/td><td>Risk-based or targeted; specialist-directed; monitoring<\/td><td>Abnormal proteins can represent nonmalignant conditions; diagnosis requires a broader workup<\/td><\/tr><tr><th>Circulating tumor DNA and other liquid biopsies<\/th><td>Blood plasma<\/td><td>Assay-specific<\/td><td>Selected treatment matching, molecular residual disease, disease-specific screening, or research<\/td><td>Specialist-directed or emerging, depending on assay<\/td><td>One \u201cliquid biopsy\u201d label covers very different tests with different evidence and regulatory status<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">What Are Cancer Blood Tests and Tumor Markers?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Cancer is not one disease, and there is no single blood test that can reliably find every cancer. \u201cCancer blood tests\u201d is a broad phrase that includes several distinct tools:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>General laboratory tests<\/strong>, such as a <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> or <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, that may show anemia, abnormal blood-cell counts, calcium changes, liver or kidney dysfunction, or treatment toxicity.<\/li>\n\n\n\n<li><strong>Circulating protein or substance markers<\/strong>, such as <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">beta-hCG<\/a>.<\/li>\n\n\n\n<li><strong>Protein-pattern tests<\/strong>, including <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">serum protein electrophoresis<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">serum free light chains<\/a>, used in selected plasma-cell-disorder evaluations.<\/li>\n\n\n\n<li><strong>Tumor-tissue and blood-based molecular biomarkers<\/strong> used to select targeted therapy, assess prognosis, or monitor molecular disease in specific cancer settings.<\/li>\n\n\n\n<li><strong>Emerging early-detection assays<\/strong> that analyze cell-free DNA, methylation, fragmentation, proteins, or other signals.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">A tumor marker can be made by cancer cells or by normal cells responding to cancer or a benign condition. This explains the central limitation: a marker may be high without cancer, and a person may have cancer without a high marker. Tumor-marker results therefore work best when the clinical question is defined before testing and when the result is interpreted with symptoms, risk, examination, imaging, pathology, treatment history, and prior values.<sup><a href=\"#ref-1\">1<\/a>, <a href=\"#ref-2\">2<\/a><\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why This Category Matters<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Confusing screening with diagnosis or monitoring can cause harm. Broad testing in people with a low pretest probability can generate false-positive results, anxiety, repeat blood draws, imaging, invasive procedures, and costs without a proven improvement in health outcomes. Conversely, a reassuring marker can create false confidence and delay evaluation of a symptom or imaging abnormality.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Focused testing can be valuable when it answers a specific question: Is the bone marrow tolerating treatment? Is kidney or liver function changing? Was a marker elevated before treatment, and is the trend consistent with response? Does a person with prostate-cancer risk want to consider <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> screening after discussing benefits and harms? Is an abnormal protein pattern contributing to unexplained anemia, kidney dysfunction, high total protein, neuropathy, or bone symptoms?<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Baselines are especially useful when a test is expected to be followed over time. A marker that was never elevated before treatment may be a poor monitoring tool for that individual. Trends also become harder to compare when laboratories, assay methods, units, or clinical circumstances change.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Screening Versus Diagnostic Support Versus Monitoring<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Educational framework\u2014not a diagnostic or treatment algorithm.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Use<\/th><th>Who is being tested?<\/th><th>Question being asked<\/th><th>Examples<\/th><th>What a result can do<\/th><th>What it cannot do<\/th><\/tr><\/thead><tbody><tr><th>Population screening<\/th><td>People without symptoms<\/td><td>Can a defined test reduce important harm when used in a defined population?<\/td><td>Mammography, cervical testing, colorectal screening, low-dose CT for eligible people, and informed <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> decisions<\/td><td>Identify people who need diagnostic follow-up<\/td><td>Diagnose cancer by itself or guarantee benefit for people outside the recommended population<\/td><\/tr><tr><th>Risk assessment<\/th><td>People with family history, exposures, inherited risk, or other factors<\/td><td>Is risk high enough to change surveillance or prevention?<\/td><td>Genetic counseling and germline testing; individualized <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> discussion<\/td><td>Refine risk and guide a professional plan<\/td><td>Show whether cancer is currently present unless a separate validated detection test is used<\/td><\/tr><tr><th>Diagnostic support<\/th><td>People with symptoms, a mass, abnormal imaging, or another concerning finding<\/td><td>What explanations fit, and what should be evaluated next?<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, selected tumor markers, <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">IFE<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a><\/td><td>Add evidence, identify organ effects, and help prioritize targeted workup<\/td><td>Replace imaging, endoscopy, bone-marrow evaluation, or biopsy\/pathology<\/td><\/tr><tr><th>Baseline and prognostic use<\/th><td>People with a confirmed or strongly suspected cancer<\/td><td>What was the marker level and organ function before treatment?<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a><\/td><td>Create a comparison point and sometimes contribute prognostic context<\/td><td>Determine stage or prognosis in isolation<\/td><\/tr><tr><th>Treatment-response monitoring<\/th><td>People receiving cancer treatment<\/td><td>Is a previously informative marker or organ-function pattern changing?<\/td><td>Serial <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>; <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> for safety<\/td><td>Support assessment of response or toxicity<\/td><td>Prove response without clinical and imaging context<\/td><\/tr><tr><th>Recurrence monitoring<\/th><td>People after treatment<\/td><td>Does a trend warrant targeted evaluation?<\/td><td>Marker-specific follow-up in defined cancers; ctDNA in selected settings<\/td><td>Prompt confirmatory imaging or specialist review<\/td><td>Establish recurrence without appropriate confirmation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">What Laboratory Testing May\u2014and Cannot\u2014Reveal<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Laboratory testing may reveal<\/th><th>Laboratory testing cannot establish by itself<\/th><th>Other evaluation that may be needed<\/th><\/tr><\/thead><tbody><tr><td>Anemia, low platelets, high or low white-cell counts, or abnormal cells<\/td><td>The cause of the blood-count pattern<\/td><td>History, examination, smear review, nutritional tests, flow cytometry, bone-marrow evaluation, or other targeted workup<\/td><\/tr><tr><td>Liver, kidney, calcium, electrolyte, and protein abnormalities<\/td><td>Whether a solid tumor caused the abnormality or where it is located<\/td><td>Repeat testing, ultrasound, CT, MRI, endoscopy, medication review, or specialist assessment<\/td><\/tr><tr><td>A marker above the laboratory interval or a change over time<\/td><td>That cancer is present, absent, growing, or recurring<\/td><td>Clinical review, method-consistent repeat testing, imaging, and sometimes biopsy<\/td><\/tr><tr><td>A monoclonal protein pattern or abnormal free-light-chain ratio<\/td><td>Whether the condition is MGUS, myeloma, another plasma-cell disorder, inflammation, or kidney-related without additional criteria<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Immunofixation<\/a>, urine studies, quantitative immunoglobulins, imaging, bone-marrow testing, and hematology review<\/td><\/tr><tr><td>A tumor-associated genomic alteration in a validated assay<\/td><td>That a therapy will work for every patient or that tissue testing is unnecessary<\/td><td>Oncology interpretation, treatment-specific labeling, and sometimes tissue confirmation<\/td><\/tr><tr><td>A cancer signal on an early-detection assay<\/td><td>A cancer diagnosis or exact site with certainty<\/td><td>Targeted imaging, procedures, pathology, and coordinated diagnostic follow-up<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Symptoms, Risk Factors, and Patient Scenarios<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Symptom, risk factor, or scenario<\/th><th>Possible explanations<\/th><th>Laboratory tests that may add information<\/th><th>Nonlaboratory evaluation that may be needed<\/th><th>Safety or urgency note<\/th><\/tr><\/thead><tbody><tr><th>Persistent unexplained fatigue, pallor, bruising, infections, or weight loss<\/th><td>Anemia, infection, inflammatory disease, medication effect, nutritional deficiency, marrow disorder, cancer, or another condition<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with differential<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, iron\/B12\/folate as indicated; specialist-directed smear, flow cytometry, or protein studies<\/td><td>History, examination, imaging, or hematology evaluation depending on findings<\/td><td>Rapidly worsening weakness, severe shortness of breath, uncontrolled bleeding, or fever during cancer treatment needs urgent care<\/td><\/tr><tr><th>Visible blood in urine, stool, sputum, or vomit; unexplained vaginal bleeding<\/th><td>Infection, stones, ulcers, hemorrhoids, medication effect, benign growths, or cancer<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, urinalysis, and targeted tests may assess consequences or alternatives<\/td><td>Prompt examination; urologic, gastrointestinal, gynecologic, pulmonary, imaging, or endoscopic evaluation<\/td><td>Heavy bleeding, fainting, black tarry stool, or coughing\/vomiting blood may be an emergency<\/td><\/tr><tr><th>New mass, enlarging lymph node, persistent focal pain, or nonhealing lesion<\/th><td>Benign mass, infection, inflammation, cyst, or malignancy<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> and selected context-specific tests<\/td><td>Physical examination, ultrasound or other imaging, and biopsy when indicated<\/td><td>Do not delay examination while waiting for a tumor-marker result<\/td><\/tr><tr><th>Jaundice, dark urine, pale stool, or persistent upper-abdominal pain<\/th><td>Gallstones, hepatitis, pancreatitis, medication injury, obstruction, or malignancy<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, bilirubin, alkaline phosphatase, AST\/ALT, lipase; <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> only in a defined professional workup<\/td><td>Prompt imaging and gastroenterology or emergency evaluation depending on severity<\/td><td>Fever with jaundice, confusion, severe pain, or persistent vomiting requires urgent assessment<\/td><\/tr><tr><th>Urinary obstruction symptoms, blood in urine or semen, pelvic or back pain, or a prostate-screening decision<\/th><td>BPH, prostatitis, urinary infection, stones, or prostate cancer<\/td><td>Urinalysis, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, and sometimes <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a> after clinical review<\/td><td>Prostate examination, urology assessment, MRI, cystoscopy, or biopsy as indicated<\/td><td>Urinary retention, fever with urinary symptoms, or severe pain needs prompt care<\/td><\/tr><tr><th>Persistent bloating, pelvic pressure, early satiety, or a pelvic mass<\/th><td>Benign gynecologic or gastrointestinal disease, pregnancy, inflammatory disease, or cancer<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>; <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> only as part of a risk-informed evaluation<\/td><td>Pelvic examination and ultrasound; specialist evaluation and pathology if a suspicious mass is found<\/td><td>Severe pain, fainting, acute bleeding, or pregnancy concerns need urgent evaluation<\/td><\/tr><tr><th>Unexplained anemia, kidney dysfunction, high total protein, bone pain, neuropathy, or recurrent fractures<\/th><td>Common metabolic, kidney, nutritional, inflammatory, or plasma-cell disorders<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, calcium, <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">serum free light chains<\/a>, and related urine tests when indicated<\/td><td>Imaging, bone-marrow evaluation, nephrology, neurology, or hematology review<\/td><td>New weakness, spinal-cord symptoms, severe hypercalcemia symptoms, or acute kidney injury requires urgent care<\/td><\/tr><tr><th>Strong family history, early-onset cancers, multiple primary cancers, or a known familial variant<\/th><td>Hereditary cancer syndrome or chance clustering<\/td><td>Germline testing selected with genetic counseling; tumor testing has a different purpose<\/td><td>Pedigree review, genetic counseling, tailored screening and prevention<\/td><td>A negative limited panel does not erase a strong family history<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Testing-Tier Overview<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Common or First-Line Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, urinalysis, and other symptom-directed tests are often used to evaluate general health patterns, organ effects, or treatment safety. They are not \u201ccancer panels\u201d and cannot exclude a malignancy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Risk-Based or Targeted Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a> may be useful when symptoms, history, an imaging finding, a confirmed diagnosis, or a specialist-defined question provides a reason to order them.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Monitoring Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Serial tumor markers can be useful when a marker is validated for the cancer type and was informative for the individual. <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> commonly monitor marrow, kidney, liver, electrolyte, and metabolic effects of treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Specialist-Directed Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tumor genomic profiling, plasma companion diagnostics, minimal or molecular residual disease assays, complex hematologic testing, and some hereditary cancer panels require disease-specific selection and interpretation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Emerging or Insufficiently Validated Tests<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Multi-cancer early-detection tests remain an evolving category. Their ability to find a signal is not the same as proof that population use reduces cancer mortality or produces more benefit than harm. A positive result requires a diagnostic pathway; a negative result does not replace established screening or symptom evaluation.<sup><a href=\"#ref-12\">12<\/a>, <a href=\"#ref-23\">23<\/a>, <a href=\"#ref-24\">24<\/a><\/sup><\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Generally Not Appropriate for Broad Routine Screening<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In average-risk, asymptomatic people, broad bundles of <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, and similar markers are generally not supported as universal cancer screening. The probability of false-positive, incidental, and uninterpretable findings rises when many nonspecific tests are ordered without a defined pretest question.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Detailed Tests and Biomarkers<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Foundational and Selected Hematology Tests<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Test or biomarker<\/th><th>Aliases<\/th><th>Use status<\/th><th>Specimen<\/th><th>What it measures<\/th><th>Why it may be ordered<\/th><th>General meaning of an abnormal result<\/th><th>Factors that may alter it<\/th><th>Preparation or timing<\/th><th>What it cannot establish by itself<\/th><th>Related guide<\/th><th>Ulta Lab Tests page<\/th><th>Primary source<\/th><\/tr><\/thead><tbody><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">Complete blood count with differential and platelets<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with differential<\/a><\/td><td>Common or first-line; monitoring<\/td><td>Blood<\/td><td>Red-cell, white-cell, and platelet counts and indices<\/td><td>Evaluate anemia, infection or marrow patterns; establish a baseline; monitor chemotherapy or other treatment effects<\/td><td>High or low counts narrow possibilities but are not cancer-specific; patterns may reflect infection, nutrition, bleeding, inflammation, medicines, marrow disease, or cancer<\/td><td>Hydration, recent illness, steroids, treatment timing, altitude, pregnancy, and specimen issues<\/td><td>Usually no fasting; compare timing relative to treatment cycles<\/td><td>Cause of an abnormal count or absence of cancer<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/blog\/blood-disorders\/cbc-anemia-blood-tests\/\">CBC and anemia blood tests<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">Complete Blood Count with Differential and Platelets Test<\/a><\/td><td><a href=\"#ref-27\">MedlinePlus CBC<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">Comprehensive metabolic panel<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a><\/td><td>Common or first-line; monitoring<\/td><td>Blood<\/td><td>Selected kidney, liver, electrolyte, protein, calcium, and glucose measures<\/td><td>Assess organ function, metabolic effects, and treatment safety; help explain nonspecific symptoms<\/td><td>Abnormalities may indicate organ dysfunction, dehydration, medication effects, obstruction, inflammation, or many other conditions<\/td><td>Fasting status, hydration, medicines, supplements, hemolysis, recent illness, and treatment<\/td><td>Follow the order\u2019s fasting instructions; do not change medicines unless instructed<\/td><td>A tumor\u2019s presence, location, type, or stage<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/blog\/liver\/liver-function-tests\/\">liver function and metabolic liver testing<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">Comprehensive Metabolic Panel Test<\/a><\/td><td><a href=\"#ref-28\">MedlinePlus CMP<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">Lactate dehydrogenase<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, LD<\/td><td>Risk-based or targeted; monitoring; specialist-directed<\/td><td>Blood<\/td><td>An enzyme released with tissue and cell injury<\/td><td>Contribute to prognosis or monitoring in selected lymphomas, germ-cell tumors, and other settings; investigate tissue injury<\/td><td>A high value is nonspecific and may reflect hemolysis, liver or muscle injury, infection, inflammation, or malignancy<\/td><td>Hemolyzed specimen, strenuous exercise, tissue injury, liver disease, infection, and many medicines<\/td><td>Avoid interpreting a hemolyzed specimen; follow assay-specific instructions<\/td><td>Cancer diagnosis, site, or recurrence<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/lymphoma\/hodgkin-lymphoma-symptoms-blood-tests-for-early-clues\/\">Hodgkin lymphoma symptoms and testing<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">Lactate Dehydrogenase Test<\/a><\/td><td><a href=\"#ref-10\">MedlinePlus LDH test<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">Serum protein electrophoresis<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">serum protein electrophoresis<\/a><\/td><td>Risk-based or targeted; specialist-directed; monitoring<\/td><td>Blood<\/td><td>Distribution of serum protein fractions and possible monoclonal protein<\/td><td>Evaluate unexplained high total protein, anemia, kidney dysfunction, bone symptoms, neuropathy, or suspected plasma-cell disorder<\/td><td>A monoclonal or abnormal pattern requires characterization and clinical correlation; polyclonal patterns often reflect inflammation or liver disease<\/td><td>Inflammation, liver disease, protein loss, immunoglobulin therapy, and specimen factors<\/td><td>Usually no fasting; compare methods and prior electrophoretic patterns<\/td><td>Multiple myeloma or another specific plasma-cell diagnosis<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/blog\/blood-disorders\/cbc-anemia-blood-tests\/\">CBC, anemia, and blood-cell testing<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">Serum Protein Electrophoresis Test<\/a><\/td><td><a href=\"#ref-29\">MedlinePlus protein electrophoresis and immunofixation<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Serum immunofixation<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">IFE<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a> electrophoresis<\/td><td>Risk-based or targeted; specialist-directed; monitoring<\/td><td>Blood<\/td><td>Type of monoclonal immunoglobulin or light chain, when present<\/td><td>Characterize an abnormal <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a> or evaluate suspected monoclonal gammopathy<\/td><td>A detected monoclonal protein may occur in MGUS, myeloma, lymphoma, amyloidosis, or other disorders<\/td><td>Recent monoclonal-antibody therapy, immunoglobulin administration, and laboratory method<\/td><td>Usually no fasting; provide treatment history<\/td><td>Whether a monoclonal protein represents cancer or requires treatment<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/blog\/blood-disorders\/cbc-anemia-blood-tests\/\">CBC, anemia, and blood-cell testing<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Serum Immunofixation Test<\/a><\/td><td><a href=\"#ref-29\">MedlinePlus protein electrophoresis and immunofixation<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">Serum free light chains with ratio<\/a><\/th><td>FLC, sFLC, kappa\/lambda ratio<\/td><td>Risk-based or targeted; specialist-directed; monitoring<\/td><td>Blood<\/td><td>Free kappa and lambda immunoglobulin light chains and their ratio<\/td><td>Complement <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">IFE<\/a> in suspected or known plasma-cell disorders; monitor selected disease<\/td><td>A markedly imbalanced ratio can support clonal-protein evaluation; both chains may rise with reduced kidney clearance or inflammation<\/td><td>Kidney function, inflammation, assay platform, and treatment<\/td><td>Usually no fasting; interpret with kidney function and the same assay when trending<\/td><td>A specific plasma-cell disorder, organ involvement, or treatment need<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/blog\/blood-disorders\/cbc-anemia-blood-tests\/\">CBC, anemia, and blood-cell testing<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">Kappa\/Lambda Free Light Chains with Ratio Blood Test<\/a><\/td><td><a href=\"#ref-11\">MedlinePlus free light chains<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">Beta-2 microglobulin<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">B2M<\/a>, \u03b22-microglobulin<\/td><td>Specialist-directed; monitoring or prognostic<\/td><td>Blood; sometimes urine or cerebrospinal fluid<\/td><td>A small protein influenced by cell turnover and kidney filtration<\/td><td>Contribute to prognosis or monitoring in multiple myeloma, chronic lymphocytic leukemia, and some lymphomas<\/td><td>High values may reflect kidney dysfunction, inflammation, infection, immune activation, or malignancy<\/td><td>Kidney function and inflammatory conditions<\/td><td>Assay-specific; interpret with creatinine\/eGFR and clinical context<\/td><td>Cancer diagnosis or stage by itself<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/lymphoma\/hodgkin-lymphoma-symptoms-blood-tests-for-early-clues\/\">Hodgkin lymphoma symptoms and testing<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">Beta-2 Microglobulin Serum Test<\/a><\/td><td><a href=\"#ref-30\">MedlinePlus B2M tumor-marker test<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Tumor-Marker Crosswalk<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Marker<\/th><th>Common aliases<\/th><th>Use status<\/th><th>Specimen<\/th><th>What it measures<\/th><th>Selected cancer contexts<\/th><th>Strongest common use<\/th><th>Noncancer causes or confounders<\/th><th>False-negative limitation<\/th><th>Broad screening role<\/th><th>Typical next-step context<\/th><th>Ulta Lab Tests page<\/th><th>Primary source<\/th><\/tr><\/thead><tbody><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a><\/th><td>Prostate-specific antigen, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a><\/td><td>Risk-based screening after shared decision-making; targeted; monitoring<\/td><td>Blood<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> produced by normal and malignant prostate cells<\/td><td>Prostate-cancer risk evaluation and monitoring<\/td><td>Monitoring known disease; informed screening in selected ages and risk settings; evaluating a persistent elevation<\/td><td>BPH, prostatitis, urinary infection, ejaculation, cycling or prostate manipulation, recent biopsy, age, and medicines that alter <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a><\/td><td>Clinically important prostate cancer can occur at a <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> below a chosen threshold<\/td><td>Not a universal automatic screen; benefits and harms should be discussed<\/td><td>Repeat under appropriate conditions, risk assessment, urology review, MRI, or biopsy depending on the whole picture<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA Total Test<\/a><\/td><td><a href=\"#ref-3\">NCI PSA fact sheet<\/a>; <a href=\"#ref-4\">USPSTF<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">Free PSA<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">percent free PSA<\/a><\/th><td>fPSA, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free-to-total PSA<\/a> ratio, % <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a><\/td><td>Risk-based or targeted adjunct<\/td><td>Blood<\/td><td>Unbound <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> relative to <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a><\/td><td>Prostate-cancer risk refinement in selected people with an elevated or borderline <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a><\/td><td>Helping a clinician discuss whether further evaluation is warranted<\/td><td>Same prostate-related confounders as <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a>; assay and decision range matter<\/td><td>No single percentage excludes clinically significant disease<\/td><td>No stand-alone population-screening role<\/td><td>Interpret with age, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a>, trend, prostate volume, examination, risk, and imaging<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">PSA Free and Total Test<\/a><\/td><td><a href=\"#ref-3\">NCI PSA fact sheet<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><\/th><td>Cancer antigen 125, ovarian cancer antigen<\/td><td>Targeted; monitoring<\/td><td>Blood<\/td><td>A glycoprotein that may rise with ovarian cancer and benign pelvic or abdominal conditions<\/td><td>Ovarian cancer; selected evaluation of a suspicious pelvic mass<\/td><td>Monitoring treatment response or recurrence when informative at baseline<\/td><td>Menstruation, pregnancy, endometriosis, fibroids, pelvic inflammatory disease, liver disease, and other benign conditions<\/td><td>Some ovarian cancers\u2014especially earlier disease\u2014do not cause a high <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><\/td><td>Not recommended for routine screening in average-risk asymptomatic women<\/td><td>Pelvic examination, ultrasound, risk assessment, gynecologic-oncology review, and pathology when indicated<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA 125 Test<\/a><\/td><td><a href=\"#ref-5\">USPSTF ovarian screening<\/a>; <a href=\"#ref-6\">MedlinePlus<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/th><td>Carcinoembryonic antigen<\/td><td>Monitoring; selected prognostic or targeted use<\/td><td>Blood<\/td><td>A glycoprotein that can rise in colorectal and several other cancers<\/td><td>Most commonly colorectal cancer; selected other cancers<\/td><td>Pretreatment baseline, treatment-response monitoring, and recurrence monitoring<\/td><td>Smoking, liver disease, inflammatory digestive or pulmonary conditions, and other benign disease<\/td><td>Many cancers do not produce an elevated <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/td><td>Not recommended as a colorectal or pan-cancer screening test<\/td><td>Compare with prior values and imaging plan; evaluate benign contributors and confirm meaningful trends<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA Test<\/a><\/td><td><a href=\"#ref-7\">MedlinePlus CEA<\/a>; <a href=\"#ref-2\">NCI list<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a><\/th><td>Alpha-fetoprotein, total <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a><\/td><td>Risk-based or targeted; monitoring<\/td><td>Blood<\/td><td>A fetal protein normally low in nonpregnant adults<\/td><td>Hepatocellular carcinoma and selected ovarian or testicular germ-cell tumors<\/td><td>Diagnostic support with imaging and other markers; treatment and recurrence monitoring<\/td><td>Pregnancy, chronic hepatitis, cirrhosis, liver regeneration, and other liver disease<\/td><td>Some liver and germ-cell tumors do not elevate <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a><\/td><td>Not a stand-alone general cancer screen; high-risk liver surveillance is specialist-guided<\/td><td>Liver imaging and hepatology review, or germ-cell-tumor workup with examination, imaging, and other markers<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">Alpha-Fetoprotein Tumor Marker Test<\/a><\/td><td><a href=\"#ref-8\">MedlinePlus AFP<\/a>; <a href=\"#ref-2\">NCI list<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a><\/th><td>Cancer antigen 19-9, carbohydrate antigen 19-9<\/td><td>Targeted; monitoring<\/td><td>Blood<\/td><td>A carbohydrate antigen associated with pancreaticobiliary and some gastrointestinal cancers<\/td><td>Pancreatic, bile-duct, gallbladder, gastric, and selected other cancers<\/td><td>Monitoring treatment, prognosis, or recurrence when elevated and clinically relevant<\/td><td>Gallstones, biliary obstruction or infection, pancreatitis, cirrhosis, liver disease, cystic fibrosis, and other conditions<\/td><td>Some people cannot produce <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> because of their Lewis antigen phenotype<\/td><td>Not a pancreatic-cancer or pan-cancer screening test<\/td><td>Evaluate jaundice or obstruction, obtain targeted imaging, and interpret after reversible biliary causes are addressed<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9 Test<\/a><\/td><td><a href=\"#ref-9\">MedlinePlus CA 19-9<\/a>; <a href=\"#ref-2\">NCI list<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">Beta-hCG<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">\u03b2-hCG<\/a>, human chorionic gonadotropin, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">quantitative hCG<\/a><\/td><td>Targeted; specialist-directed; monitoring<\/td><td>Blood or urine<\/td><td>Human chorionic gonadotropin<\/td><td>Gestational trophoblastic disease and selected germ-cell tumors<\/td><td>Staging, prognostic assessment, treatment response, and recurrence monitoring in defined contexts<\/td><td>Pregnancy, recent pregnancy loss, fertility treatment, assay interference, pituitary <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>, and rare other causes<\/td><td>Not all germ-cell tumors produce <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a><\/td><td>No broad routine cancer-screening role<\/td><td>First clarify pregnancy context and assay validity; coordinate tumor evaluation with oncology, gynecology, or urology<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG Total Quantitative Test<\/a><\/td><td><a href=\"#ref-2\">NCI tumor-marker list<\/a><\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a><\/th><td>LD, <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">lactate dehydrogenase<\/a><\/td><td>Targeted; monitoring; prognostic<\/td><td>Blood<\/td><td>A nonspecific enzyme released with cell or tissue injury<\/td><td>Selected lymphomas, leukemias, germ-cell tumors, melanoma, and other contexts<\/td><td>Contributing to prognosis or tracking disease burden in a defined diagnosis<\/td><td>Hemolysis, exercise, muscle or liver injury, infection, inflammation, and many other conditions<\/td><td>Normal <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a> does not exclude cancer or active disease<\/td><td>No useful stand-alone broad screening role<\/td><td>Repeat if specimen hemolysis is suspected and interpret with diagnosis-specific criteria<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">Lactate Dehydrogenase Test<\/a><\/td><td><a href=\"#ref-10\">MedlinePlus LDH<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">\u201cCancer Marker Elevated\u201d Does Not Equal Cancer<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Educational framework\u2014not a diagnostic or treatment algorithm.<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Verify the exact test, unit, flag, and reference interval.<\/strong> Similar names may represent different assays, and a laboratory flag is not a diagnosis.<\/li>\n\n\n\n<li><strong>Ask why the test was ordered.<\/strong> A result obtained for monitoring known cancer has a different pretest probability and meaning than the same result ordered as general reassurance.<\/li>\n\n\n\n<li><strong>Check for immediate clinical urgency.<\/strong> Severe symptoms, active bleeding, jaundice with fever, neurologic deficits, urinary obstruction, or rapid deterioration should not wait for routine repeat testing.<\/li>\n\n\n\n<li><strong>Review benign causes and preparation.<\/strong> Infection, inflammation, smoking, pregnancy, menstruation, liver or kidney disease, biliary obstruction, recent procedures, exercise, and medicines may matter.<\/li>\n\n\n\n<li><strong>Compare with prior values and assay method.<\/strong> A stable mild elevation may carry different information from a reproducible, rapidly changing trend, but neither pattern is diagnostic by itself.<\/li>\n\n\n\n<li><strong>Confirm when appropriate.<\/strong> A clinician may repeat the test\u2014often using the same laboratory and method\u2014after addressing a temporary confounder or verifying specimen quality.<\/li>\n\n\n\n<li><strong>Pair the marker with the correct evaluation.<\/strong> Depending on context, this may include examination, <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, ultrasound, CT, MRI, endoscopy, cystoscopy, mammography, or another focused procedure.<\/li>\n\n\n\n<li><strong>Use specialist interpretation when the consequence is important.<\/strong> Oncology, hematology, urology, gynecology, gastroenterology, hepatology, genetics, or another specialty may be needed.<\/li>\n\n\n\n<li><strong>Use pathology to establish many diagnoses.<\/strong> When a suspicious lesion is found, biopsy and pathologist review are often required to determine whether cancer is present and what type it is.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">Routine Cancer Screening Recommendations Versus Tumor-Marker Use<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The table below summarizes major U.S. population-screening concepts revalidated on August 7, 2026. Recommendations differ by organization, risk, age, health status, and new evidence; use current professional guidance for individual decisions.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Cancer type<\/th><th>Routine screening approach for average-risk or defined-risk populations<\/th><th>Role of traditional serum tumor markers<\/th><th>Important follow-up or limitation<\/th><th>Source<\/th><\/tr><\/thead><tbody><tr><th>Breast<\/th><td>USPSTF recommends biennial mammography for women ages 40 through 74; higher-risk plans differ<\/td><td>CA 15-3, CA 27.29, and <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> are not substitutes for screening mammography<\/td><td>An abnormal mammogram requires diagnostic breast imaging and sometimes biopsy<\/td><td><a href=\"#ref-18\">USPSTF breast screening<\/a><\/td><\/tr><tr><th>Cervical<\/th><td>Cervical cytology and\/or high-risk HPV testing at guideline-defined ages and intervals<\/td><td>No serum tumor marker replaces cervical screening<\/td><td>An abnormal screen may require repeat testing, colposcopy, and biopsy<\/td><td><a href=\"#ref-21\">USPSTF cervical screening<\/a><\/td><\/tr><tr><th>Colorectal<\/th><td>USPSTF recommends screening beginning at age 45 for average-risk adults. Stool-based and visual options remain established. ACS 2026 guidance places an FDA-approved blood-based option after preferred stool or visual testing for people who decline or do not complete those options.<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> is not a colorectal-cancer screening test<\/td><td>Every positive non-colonoscopy screen requires timely colonoscopy; disease-specific blood screening is not a universal tumor-marker panel<\/td><td><a href=\"#ref-16\">ACS guidance<\/a>; <a href=\"#ref-17\">ACS 2026 guideline<\/a>; <a href=\"#ref-19\">USPSTF<\/a>; <a href=\"#ref-14\">FDA<\/a><\/td><\/tr><tr><th>Lung<\/th><td>Annual low-dose CT for adults meeting current age, smoking-history, and current\/recent-smoking criteria<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, CYFRA 21-1, and other circulating markers do not replace low-dose CT screening<\/td><td>Nodules require imaging-based follow-up; symptoms require diagnostic evaluation regardless of eligibility<\/td><td><a href=\"#ref-20\">USPSTF lung screening<\/a><\/td><\/tr><tr><th>Prostate<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>-based screening is an individual decision for ages 55\u201369 under current USPSTF guidance; it is not recommended at age 70 or older by USPSTF<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> is the partial exception among traditional markers because it may be used for informed screening; <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a> is an adjunct, not a stand-alone screen<\/td><td>Discuss overdiagnosis, false positives, biopsy harms, and individual risk<\/td><td><a href=\"#ref-3\">NCI<\/a>; <a href=\"#ref-4\">USPSTF<\/a><\/td><\/tr><tr><th>Ovarian<\/th><td>No routine screening is recommended for average-risk asymptomatic women<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> is primarily a monitoring test and a targeted adjunct in selected pelvic-mass or high-risk contexts<\/td><td>Symptoms or a mass require examination and imaging; a high <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> is not diagnostic<\/td><td><a href=\"#ref-5\">USPSTF<\/a>; <a href=\"#ref-6\">MedlinePlus<\/a><\/td><\/tr><tr><th>Pancreatic<\/th><td>USPSTF recommends against screening asymptomatic average-risk adults; surveillance for selected high-risk people is specialist-directed<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> is not a pancreatic-cancer screening test<\/td><td>Jaundice, weight loss, or persistent pain requires prompt imaging and clinical evaluation<\/td><td><a href=\"#ref-22\">USPSTF<\/a>; <a href=\"#ref-9\">MedlinePlus<\/a><\/td><\/tr><tr><th>Liver<\/th><td>No broad average-risk screening program; people with cirrhosis or selected chronic liver risks may follow hepatology surveillance guidance<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a> may supplement imaging in selected high-risk contexts but is not a stand-alone general screen<\/td><td>Chronic hepatitis and cirrhosis can elevate <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>; imaging remains central<\/td><td><a href=\"#ref-8\">MedlinePlus AFP<\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Emerging Liquid-Biopsy Evidence Matrix<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Liquid-biopsy use<\/th><th>Population and question<\/th><th>Current use status<\/th><th>Evidence or regulatory example<\/th><th>Key limitation<\/th><th>Patient takeaway<\/th><\/tr><\/thead><tbody><tr><th>Plasma companion diagnostic for treatment selection<\/th><td>Person with a known cancer: Is a specific actionable tumor alteration present?<\/td><td>Established in selected cancers and drugs; specialist-directed<\/td><td>FDA lists authorized plasma companion diagnostics for defined tumor-drug combinations.<sup><a href=\"#ref-13\">13<\/a><\/sup><\/td><td>A negative plasma result may not exclude an alteration; tissue testing may still be needed, and the result applies only to labeled contexts<\/td><td>This is precision-oncology testing\u2014not general cancer screening<\/td><\/tr><tr><th>ctDNA molecular residual disease or recurrence assessment<\/th><td>Person treated for a known cancer: Is tumor-associated DNA still detectable?<\/td><td>Established or emerging depending on cancer, assay, and decision<\/td><td>In May 2026, FDA authorized a ctDNA MRD companion diagnostic for a specific adjuvant-treatment decision after cystectomy in muscle-invasive bladder cancer.<sup><a href=\"#ref-15\">15<\/a><\/sup><\/td><td>Evidence and actionability are disease- and treatment-specific; a negative result does not guarantee cure<\/td><td>Use only within a defined oncology plan<\/td><\/tr><tr><th>Disease-specific blood-based colorectal screening<\/th><td>Average-risk adult meeting a product\u2019s indication: Can a validated blood assay identify a colorectal-cancer signal?<\/td><td>FDA-approved option exists; current guideline placement is narrower than preferred stool or visual tests<\/td><td>FDA\u2019s Shield approval applies to adults age 45 or older at average risk; positive results require colonoscopy, and negative results do not end screening.<sup><a href=\"#ref-14\">14<\/a>, <a href=\"#ref-16\">16<\/a>, <a href=\"#ref-17\">17<\/a><\/sup><\/td><td>Limited precancer detection and false positives; not for high-risk surveillance or diagnostic colonoscopy replacement<\/td><td>A disease-specific approved screening assay is not the same as a traditional <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> test or an MCED panel<\/td><\/tr><tr><th>Multi-cancer early-detection testing<\/th><td>Asymptomatic person: Can one assay detect signals from several cancers and suggest a tissue of origin?<\/td><td>Emerging or insufficiently validated for broad routine screening<\/td><td>Prospective studies show feasibility; Galleri\u2019s PMA was submitted in January 2026. The randomized NHS-Galleri trial did not meet its primary endpoint, although secondary findings remain under study.<sup><a href=\"#ref-12\">12<\/a>, <a href=\"#ref-24\">24<\/a>\u2013<a href=\"#ref-26\">26<\/a><\/sup><\/td><td>Mortality benefit, overdiagnosis, downstream harms, false negatives, diagnostic pathways, equity, and cost-effectiveness remain unresolved<\/td><td>Do not use an MCED result to replace established screening or evaluation of symptoms<\/td><\/tr><tr><th>Research-only recurrence, response, or early-detection signatures<\/th><td>Clinical-trial participant or narrowly selected patient<\/td><td>Research or assay-specific<\/td><td>Studies examine methylation, fragmentation, mutations, proteins, and combined signals<\/td><td>Analytical validity does not automatically establish clinical utility<\/td><td>Ask whether the assay is FDA authorized for the proposed use, guideline supported, and linked to a defined action<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Regulatory update warning:<\/strong> This field changes rapidly. Recheck FDA databases, current product labeling, and current professional guidelines immediately before publication. Do not infer an intended use from a press release, product name, or broad category description.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Test-Selection Framework<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Educational framework\u2014not a diagnostic or treatment algorithm.<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Define the patient question.<\/strong> Is the goal guideline-based screening, risk assessment, symptom evaluation, a baseline before treatment, treatment-safety monitoring, response monitoring, or recurrence surveillance?<\/li>\n\n\n\n<li><strong>Estimate pretest probability.<\/strong> Consider age, symptoms, examination, personal history, family history, inherited variants, exposures, prior cancer, imaging, and previous laboratory results.<\/li>\n\n\n\n<li><strong>Choose the test whose validated use matches the question.<\/strong> A marker used to monitor known colorectal cancer should not automatically be repurposed to screen an asymptomatic person.<\/li>\n\n\n\n<li><strong>Ask what will happen after each possible result.<\/strong> Before ordering, identify the appropriate response to a normal, mildly abnormal, markedly abnormal, rising, falling, or discordant result.<\/li>\n\n\n\n<li><strong>Consider the cost of error.<\/strong> Could a false positive lead to unnecessary imaging or biopsy? Could a false negative falsely reassure someone with concerning symptoms?<\/li>\n\n\n\n<li><strong>Prefer the smallest focused set that answers the question.<\/strong> Adding unrelated markers may increase incidental findings without increasing useful information.<\/li>\n\n\n\n<li><strong>Account for preparation and confounders.<\/strong> Review acute illness, pregnancy, menstrual timing, prostate procedures, smoking, liver or kidney disease, treatment timing, medications, supplements, and assay methodology.<\/li>\n\n\n\n<li><strong>Plan confirmation.<\/strong> Decide whether a meaningful result requires repeat testing, another assay, imaging, endoscopy, pathology, genetic counseling, or specialist referral.<\/li>\n\n\n\n<li><strong>Use trends responsibly.<\/strong> When monitoring is appropriate, use the same assay when feasible and interpret changes with symptoms, examination, imaging, and treatment timing.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">Individual Test Versus Panel Comparison<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Testing option<\/th><th>Typical contents or focus<\/th><th>When it may be useful<\/th><th>Advantages<\/th><th>Limitations<\/th><th>Risk of incidental findings<\/th><th>Questions to ask before ordering<\/th><\/tr><\/thead><tbody><tr><th>Single general test<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, or another symptom-directed laboratory test<\/td><td>Initial evaluation, baseline, or treatment-safety monitoring<\/td><td>Focused, familiar, and often easy to trend<\/td><td>Nonspecific; a normal result does not exclude cancer<\/td><td>Low to moderate<\/td><td>What clinical question will this answer? What noncancer causes are more likely?<\/td><\/tr><tr><th>Single tumor marker<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>, or another defined marker<\/td><td>When the marker has a validated role in the person\u2019s screening discussion, diagnostic workup, or known cancer<\/td><td>Clearer reason for testing and easier trend interpretation<\/td><td>False positives and false negatives; not diagnostic by itself<\/td><td>Moderate when pretest probability is low<\/td><td>Is this marker recommended for my exact use? What follow-up will occur if it is high or normal?<\/td><\/tr><tr><th>Focused paired or reflex testing<\/th><td>Total plus <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a>; <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a> plus <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a> and reflex <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>; tumor-specific marker combinations<\/td><td>When one result changes the interpretation or triggers a defined next test<\/td><td>Can improve efficiency and reduce incomplete workups<\/td><td>Reflex rules, methods, and clinical utility must be verified<\/td><td>Moderate<\/td><td>What triggers the reflex? Are all components indicated? Will kidney function or another factor affect interpretation?<\/td><\/tr><tr><th>General organ-function panel<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, and selected urinalysis or inflammation tests<\/td><td>Baseline or treatment-safety assessment<\/td><td>Provides broad organ context<\/td><td>Not a cancer screen; may reveal unrelated abnormalities<\/td><td>Moderate<\/td><td>Which components are needed? Is fasting required? How will incidental abnormalities be handled?<\/td><\/tr><tr><th>Multi-tumor-marker panel<\/th><td>Several traditional markers, sometimes with <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>\/<a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> or stool testing<\/td><td>Only when each component has a defined reason and a plan for follow-up<\/td><td>Single order may collect several clinically justified measures<\/td><td>Not validated as a universal cancer screen; panel names may overstate what components can do<\/td><td>High when ordered in low-risk asymptomatic people<\/td><td>Which guideline supports each component? What is the false-positive burden? Does this replace any established screen? It should not.<\/td><\/tr><tr><th>Genomic or liquid-biopsy assay<\/th><td>Tumor alterations, ctDNA MRD, disease-specific screening signal, or MCED signature<\/td><td>Assay-specific treatment, monitoring, or screening context<\/td><td>May capture molecular information not available from a conventional protein marker<\/td><td>Regulatory status and evidence vary widely; downstream workup may be complex<\/td><td>Moderate to high, depending on use<\/td><td>Is it FDA authorized for this exact use? Is it guideline supported? What does a positive or negative result trigger?<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Panel-content note:<\/strong> Verify the exact contents, specimen requirements, reflex rules, and current product name of every Ulta Lab Tests panel immediately before publication. A larger or more expensive panel is not automatically better.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Test-Name and Alias Crosswalk<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Common report name<\/th><th>Aliases or abbreviations<\/th><th>Do not confuse with<\/th><th>Key context<\/th><\/tr><\/thead><tbody><tr><th>Prostate-specific antigen<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA, total<\/a> <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, tPSA<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">Free PSA<\/a> or <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">percent free PSA<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">Total PSA<\/a> is the main measured concentration; <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a> is an adjunct in selected cases<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">Free PSA<\/a><\/th><td>fPSA, % <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free-to-total PSA<\/a> ratio<\/td><td>A separate cancer diagnosis<\/td><td>Interpret only with <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a> and clinical risk<\/td><\/tr><tr><th>Cancer antigen 125<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA 125<\/a>, ovarian cancer antigen<\/td><td>A definitive ovarian-cancer test<\/td><td>Most commonly used for monitoring known disease<\/td><\/tr><tr><th>Carcinoembryonic antigen<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> assay<\/td><td>Colorectal screening<\/td><td>Primarily a monitoring marker in known cancer<\/td><\/tr><tr><th>Alpha-fetoprotein<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, total <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a><\/td><td>Prenatal <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a> or <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>-L3%<\/td><td>The clinical meaning depends on pregnancy and liver or germ-cell-tumor context<\/td><\/tr><tr><th>Cancer antigen 19-9<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA19-9<\/a>, carbohydrate antigen 19-9<\/td><td>A pancreatic-cancer screen<\/td><td>Biliary obstruction and Lewis antigen status matter<\/td><\/tr><tr><th>Human chorionic gonadotropin<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">beta-hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">\u03b2-hCG<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">quantitative hCG<\/a><\/td><td>Pregnancy testing alone<\/td><td>Pregnancy context must be resolved before tumor interpretation<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">Lactate dehydrogenase<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, LD<\/td><td>Lactic acid or lactate<\/td><td>Nonspecific tissue-injury marker used in selected oncology settings<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">Serum protein electrophoresis<\/a><\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a>, serum PEP<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Immunofixation<\/a><\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a> detects and quantifies patterns; <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">IFE<\/a> characterizes a monoclonal protein<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Immunofixation<\/a> electrophoresis<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">IFE<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">serum immunofixation<\/a><\/td><td>Quantitative immunoglobulins<\/td><td>Identifies immunoglobulin type when an abnormal band is present<\/td><\/tr><tr><th><a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">Serum free light chains<\/a><\/th><td>sFLC, FLC, kappa\/lambda ratio<\/td><td>Total immunoglobulin light chains<\/td><td>Kidney function and assay method materially affect interpretation<\/td><\/tr><tr><th>Circulating tumor DNA<\/th><td>ctDNA, tumor-informed MRD, plasma genotyping<\/td><td>Cell-free DNA generally or germline testing<\/td><td>Different assays answer treatment, monitoring, or screening questions<\/td><\/tr><tr><th>Multi-cancer early detection<\/th><td>MCED, MCD, multi-cancer detection<\/td><td>A universal diagnostic test<\/td><td>Positive results require diagnostic workup; negative results do not replace established screening<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Preparation and Interference Matrix<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Tests commonly affected<\/th><th>How the factor may alter results<\/th><th>General preparation guidance<\/th><th>Important caution<\/th><\/tr><\/thead><tbody><tr><th>Fasting<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> components and tests bundled with glucose, insulin, or lipids<\/td><td>Food can change glucose, triglycerides, and some chemistry results; most tumor markers do not require fasting by themselves<\/td><td>Follow the exact order instructions and record fasting status<\/td><td>Do not fast unnecessarily if it could be unsafe<\/td><\/tr><tr><th>Hydration<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, total protein, calcium, and kidney measures<\/td><td>Dehydration may concentrate some results; overhydration may dilute them<\/td><td>Use normal hydration unless a clinician has given fluid restrictions<\/td><td>Heart or kidney conditions may require individualized fluid guidance<\/td><\/tr><tr><th>Recent illness, infection, inflammation, or surgery<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a>, and others<\/td><td>Can create transient abnormalities unrelated to cancer<\/td><td>Tell the ordering professional and laboratory about recent events<\/td><td>Do not postpone urgent diagnostic evaluation merely to obtain a \u201ccleaner\u201d result<\/td><\/tr><tr><th>Ejaculation, cycling, urinary infection, catheterization, prostate examination, biopsy, or procedure<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a><\/td><td>May temporarily increase <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>; some prostate medicines may lower it<\/td><td>Ask for test-specific timing guidance and provide procedure and symptom history<\/td><td>Never stop a prescription medicine without the prescriber\u2019s guidance<\/td><\/tr><tr><th>Menstruation, pregnancy, endometriosis, fibroids, or pelvic inflammation<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><\/td><td>May increase <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> without ovarian cancer<\/td><td>Record cycle, pregnancy, and pelvic-condition context<\/td><td>A concerning mass or persistent symptoms still require imaging and evaluation<\/td><\/tr><tr><th>Pregnancy or recent pregnancy<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>; sometimes <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a><\/td><td>Physiologic elevations can overlap with tumor-marker interpretations<\/td><td>Clarify pregnancy status and gestational context before interpretation<\/td><td>An unexpected <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a> result may require repeat testing and clinical evaluation; do not assume cancer<\/td><\/tr><tr><th>Smoking<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/td><td>May produce a higher baseline <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/td><td>Record current and recent smoking status<\/td><td>Smoking status does not make a rising or markedly abnormal trend self-explanatory<\/td><\/tr><tr><th>Biliary obstruction, cholangitis, pancreatitis, or gallstones<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> and liver chemistries<\/td><td>Can substantially elevate <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> and cholestatic liver tests<\/td><td>Interpret with bilirubin, alkaline phosphatase, symptoms, and imaging<\/td><td>Fever plus jaundice or severe pain may require urgent care<\/td><\/tr><tr><th>Chronic hepatitis, cirrhosis, or liver injury<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a><\/td><td>May elevate markers or alter proteins without cancer<\/td><td>Interpret with liver history, imaging, and trend<\/td><td>A marker alone cannot distinguish inflammation, regeneration, obstruction, and malignancy<\/td><\/tr><tr><th>Kidney dysfunction<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">Free light chains<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">beta-2 microglobulin<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a><\/td><td>Reduced clearance may raise both <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">beta-2 microglobulin<\/a><\/td><td>Interpret with creatinine\/eGFR and kidney-adjusted clinical context<\/td><td>An abnormal ratio or protein pattern still deserves appropriate review<\/td><\/tr><tr><th>Recent strenuous exercise or specimen hemolysis<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a>, AST, potassium, <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> and other chemistry results<\/td><td>May increase <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a> and other analytes; hemolysis can invalidate interpretation<\/td><td>Avoid unusual strenuous exercise if instructed and ask whether a hemolyzed sample should be recollected<\/td><td>Do not dismiss severe symptoms as an exercise effect without evaluation<\/td><\/tr><tr><th>Biotin, vitamins, supplements, and assay-interfering antibodies<\/th><td>Some immunoassays, depending on platform<\/td><td>May cause falsely high or low results<\/td><td>Provide a complete list and ask the laboratory or clinician about assay-specific interference<\/td><td>Do not stop supplements or medicines solely from general internet advice<\/td><\/tr><tr><th>Cancer treatment and treatment-cycle timing<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a>, markers, ctDNA, and protein studies<\/td><td>Expected nadirs, recovery, tumor lysis, organ toxicity, and response can change results<\/td><td>Collect at the oncology team\u2019s specified interval<\/td><td>Fever, bleeding, severe weakness, dehydration, or new neurologic symptoms during treatment may be urgent<\/td><\/tr><tr><th>Laboratory method and specimen handling<\/th><td>All markers, especially serial results<\/td><td>Different platforms, calibrations, units, and handling can create apparent changes<\/td><td>Trend with the same method when feasible and review method changes<\/td><td>Do not calculate a percentage change across incompatible methods without professional review<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">How to Understand Your Results<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A laboratory <strong>reference interval<\/strong> describes the range expected in a defined reference population using a specific method. It is not automatically a cancer cutoff. A <strong>screening cutoff<\/strong> is selected to balance sensitivity, specificity, and downstream consequences in a defined population. A <strong>diagnostic threshold<\/strong> may be one part of formal criteria, while a <strong>treatment or monitoring target<\/strong> reflects a management goal. These concepts can differ.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Interpretation also depends on biological variation within a person, analytical variation in the assay, and preanalytical variation from collection, transport, preparation, and timing. Review the test name, value, unit, flag, reference interval, method, prior values, clinical reason, and related results together. The guide to <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/how-to-read-lab-results\/\">reading laboratory values, ranges, flags, and trends<\/a> explains these concepts in more depth.<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Term<\/th><th>What it means<\/th><th>How it is established<\/th><th>How it is used<\/th><th>Why it may differ<\/th><th>Patient caution<\/th><\/tr><\/thead><tbody><tr><th>Reference interval<\/th><td>Values expected in a defined reference population for that assay<\/td><td>Laboratory method and reference-population studies<\/td><td>Flags results for review<\/td><td>Population, method, age, sex, pregnancy, and laboratory<\/td><td>Inside the interval does not guarantee health; outside does not prove disease<\/td><\/tr><tr><th>Screening cutoff<\/th><td>A value or category that triggers follow-up in a defined screening program<\/td><td>Outcome studies balancing detection and harms<\/td><td>Separates screen-negative from screen-positive<\/td><td>Guideline, population, test version, and risk<\/td><td>A positive screen is not a diagnosis<\/td><\/tr><tr><th>Diagnostic threshold or criterion<\/th><td>A value contributing to a diagnosis when combined with other criteria<\/td><td>Clinical validation and consensus criteria<\/td><td>Supports diagnostic classification<\/td><td>Disease definition, assay, and evidence updates<\/td><td>Many cancers still require imaging and pathology<\/td><\/tr><tr><th>Pretreatment baseline<\/th><td>Result measured before therapy<\/td><td>Individual patient measurement<\/td><td>Comparison with later values<\/td><td>Timing, disease burden, temporary confounders, and method<\/td><td>A marker not elevated at baseline may not be useful for monitoring<\/td><\/tr><tr><th>Monitoring target or trend<\/th><td>Expected or concerning pattern during or after treatment<\/td><td>Disease- and treatment-specific evidence<\/td><td>Supports response, toxicity, or recurrence assessment<\/td><td>Timing, therapy, assay, and imaging findings<\/td><td>One change rarely determines treatment by itself<\/td><\/tr><tr><th>Reference change or meaningful trend<\/th><td>A change larger than expected from ordinary variation<\/td><td>Biological and analytical-variation data plus clinical context<\/td><td>Helps distinguish signal from noise<\/td><td>Assay precision, interval, baseline, and individual biology<\/td><td>\u201cRising\u201d is not automatically \u201ccancer growing\u201d<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">Fictional Tumor-Marker Report Walkthrough<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Educational example only. The values, patient, and circumstances are fictional. No universal reference interval is implied.<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Report element<\/th><th>Fictional entry<\/th><th>Questions raised<\/th><\/tr><\/thead><tbody><tr><th>Test<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a><\/td><td>Was this ordered to monitor a known <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>-producing cancer, or as general screening?<\/td><\/tr><tr><th>Value and unit<\/th><td>Mildly above this laboratory\u2019s stated upper limit, in ng\/mL<\/td><td>What is the exact method and interval? Was the same assay used previously?<\/td><\/tr><tr><th>Flag<\/th><td>H<\/td><td>A high flag identifies a value outside the interval; it does not identify the cause<\/td><\/tr><tr><th>Prior result<\/th><td>No prior <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> result available<\/td><td>Without a baseline, a trend cannot be assessed<\/td><\/tr><tr><th>Related results<\/th><td><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> without a major abnormality; mild liver-enzyme elevation on <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a><\/td><td>Could liver, digestive, inflammatory, or medication factors contribute? Are there symptoms or imaging findings?<\/td><\/tr><tr><th>Preparation and history<\/th><td>Smoking status, recent illness, and reason for ordering not documented<\/td><td>These missing details materially limit interpretation<\/td><\/tr><tr><th>Possible professional follow-up<\/th><td>Review indication and symptoms; assess benign contributors; confirm or repeat only when appropriate; use guideline-based colorectal screening; obtain targeted imaging or endoscopy only when clinically indicated<\/td><td><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> should not be used to diagnose or exclude colorectal cancer<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The safest interpretation is not \u201ccancer\u201d or \u201cno cancer.\u201d It is: <em>a mildly abnormal, nonspecific result with insufficient context<\/em>. The next step depends on why it was ordered, the patient\u2019s symptoms and risk, related tests, preparation, and whether the result is reproducible.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">When Not to Order Tumor Markers<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Do not order a broad marker bundle simply to \u201ccheck for all cancers.\u201d<\/strong> No conventional panel can do this reliably.<\/li>\n\n\n\n<li><strong>Do not substitute markers for established screening.<\/strong> <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> does not replace colorectal screening; <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> does not replace risk-appropriate gynecologic evaluation; <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> does not replace pancreatic imaging; serum markers do not replace mammography, cervical testing, or low-dose CT.<\/li>\n\n\n\n<li><strong>Do not use a normal marker to dismiss persistent or concerning symptoms.<\/strong> Many cancers do not release a measurable marker.<\/li>\n\n\n\n<li><strong>Do not use an abnormal marker as proof of cancer.<\/strong> Confirm the context and evaluate benign causes before escalating appropriately.<\/li>\n\n\n\n<li><strong>Do not order a monitoring marker that was never informative for the confirmed cancer<\/strong> unless the treating team has a defined reason.<\/li>\n\n\n\n<li><strong>Do not repeat a marker at arbitrary short intervals.<\/strong> Timing should reflect biology, treatment, assay variation, and a management plan.<\/li>\n\n\n\n<li><strong>Do not duplicate tests with overlapping names without understanding the difference.<\/strong> Examples include total versus <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP tumor marker<\/a> versus prenatal <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">SPEP<\/a> versus <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>.<\/li>\n\n\n\n<li><strong>Do not ignore an acute confounder.<\/strong> Infection, biliary obstruction, pregnancy, kidney dysfunction, liver disease, or specimen hemolysis may dominate interpretation.<\/li>\n\n\n\n<li><strong>Do not order specialist molecular assays without an action plan.<\/strong> Ask whether the result is validated for the cancer, treatment, and decision under consideration.<\/li>\n\n\n\n<li><strong>Do not use routine outpatient testing when urgent evaluation is needed.<\/strong> Severe bleeding, respiratory distress, jaundice with fever, new neurologic deficits, spinal-cord symptoms, urinary retention, or rapid deterioration require prompt care.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">When Repeat or Confirmatory Testing May Be Needed<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Repeat testing is useful only when it can answer a defined question. The appropriate interval depends on the marker, reason for testing, expected biological change, treatment schedule, laboratory method, and urgency.<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Verify the indication.<\/strong> Clarify whether the first result was obtained for screening, symptom evaluation, a pretreatment baseline, treatment monitoring, or recurrence surveillance.<\/li>\n\n\n\n<li><strong>Review preanalytical factors.<\/strong> Check specimen quality, collection timing, pregnancy status when relevant, recent procedures, infection, inflammation, smoking, liver or kidney dysfunction, medicines, and supplements.<\/li>\n\n\n\n<li><strong>Compare like with like.<\/strong> A trend is easiest to interpret when the same marker, specimen type, assay method, and preferably laboratory are used.<\/li>\n\n\n\n<li><strong>Use a complementary test when needed.<\/strong> An abnormal <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> may lead to repeat <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free-to-total PSA<\/a>, examination, imaging, or urologic evaluation. A monoclonal-protein pattern may require <a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">immunofixation<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">free light chains<\/a>, urine studies, imaging, and hematology review.<\/li>\n\n\n\n<li><strong>Do not delay definitive evaluation.<\/strong> When symptoms, examination, or imaging are concerning, repeating a nonspecific marker should not postpone a more appropriate procedure such as imaging, endoscopy, or biopsy.<\/li>\n\n\n\n<li><strong>Interpret discordance.<\/strong> A rising marker with stable imaging, or abnormal imaging with a normal marker, requires clinical reconciliation\u2014not automatic acceptance of one result over the other.<\/li>\n<\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Marked or rapidly changing abnormalities generally deserve more prompt review than small isolated changes, but the number alone cannot define urgency without the clinical setting.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">When Professional or Urgent Care Is Needed<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Arrange timely professional evaluation for a persistent unexplained symptom, a new mass, unexplained bleeding, progressive swallowing difficulty, persistent change in bowel or bladder habits, unexplained weight loss, persistent jaundice, worsening bone pain, drenching night sweats, persistent lymph-node enlargement, or a materially abnormal result. These findings do not prove cancer, but routine self-directed marker testing is not an adequate evaluation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Seek urgent or emergency care<\/strong> for severe or uncontrolled bleeding, coughing or vomiting blood, new confusion or one-sided weakness, new loss of bladder or bowel control with back pain or weakness, severe shortness of breath, a painful swollen limb with breathing symptoms, urinary obstruction, jaundice with fever or severe abdominal pain, or rapid clinical deterioration. A person receiving cancer treatment should follow the oncology team\u2019s instructions for fever, infection symptoms, bleeding, dehydration, chest pain, breathing difficulty, or other treatment-specific warning signs.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Explore the Cancer-Related Blood Tests and Tumor Markers Knowledge Center<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The focused pages below answer narrower questions without turning this pillar into a condition-by-condition cancer encyclopedia. Existing links should be rechecked immediately before publication.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/prostate-cancer\/psa-levels-explained\/\">PSA Levels Explained<\/a><\/strong> \u2014 Explains <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a> patterns, age and prostate context, benign causes of elevation, trends, and common follow-up questions. <em>Status: retain and medically update.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> Free Versus Total<\/strong> \u2014 Proposed page explaining <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">percent-free PSA<\/a>, when it may add context after an abnormal <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a>, assay limitations, and why it does not diagnose prostate cancer. <em>Status: create; proposed URL: \/blog\/cancer\/prostate-cancer\/<a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">psa<\/a>-free-vs-total\/.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/prostate-cancer\/prostate-cancer-symptoms-detection\/\">Prostate Cancer Symptoms and Detection<\/a><\/strong> \u2014 Reviews symptoms, risk, <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>\u2019s role, and why symptoms may be absent early. <em>Status: retain and update.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/breast-cancer\/how-can-i-reduce-my-breast-cancer-risk\/\">Breast Cancer Risk<\/a><\/strong> \u2014 Discusses modifiable and nonmodifiable risk, screening conversations, and when hereditary-risk assessment may matter. <em>Status: update to current screening guidance and remove unsupported laboratory-screening implications.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/key-symptoms-of-pancreatic-cancer-to-watch-for\/\">Pancreatic Cancer Symptoms<\/a><\/strong> \u2014 Reviews warning signs and explains why <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> is not a population screening test. <em>Status: retain and substantially update.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/bladder-cancer-the-5-warning-signs\/\">Bladder Cancer Warning Signs<\/a><\/strong> \u2014 Focuses on blood in the urine, urinary symptoms, and the need for urinalysis, imaging, and urologic evaluation rather than reliance on blood markers. <em>Status: retain and update.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/lymphoma\/hodgkin-lymphoma-symptoms-blood-tests-for-early-clues\/\">Hodgkin Lymphoma<\/a><\/strong> \u2014 Explains symptom patterns, <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a> context, and why diagnosis requires tissue pathology. <em>Status: retain and update.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/thyroid\/thyroid-cancer\/six-common-thyroid-cancer-symptoms\/\">Thyroid Cancer Symptoms<\/a><\/strong> \u2014 Reviews neck findings, thyroid testing limitations, ultrasound, and biopsy. <em>Status: retain but medically rewrite to avoid using thyroid-function blood tests as cancer screens.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/blood-testing-for-hormone-sensitive-cancers-a-key-to-early-detection\/\">Hormone-Sensitive Cancers<\/a><\/strong> \u2014 Distinguishes hormone-receptor biology from circulating hormone levels and explains when laboratory testing supports\u2014not establishes\u2014oncologic decisions. <em>Status: retain as a narrow subpillar and substantially rewrite.<\/em><\/li>\n\n\n\n<li><strong><a href=\"https:\/\/www.ultalabtests.com\/blog\/genomic-testing\/genetic-genomic-testing\/\">Hereditary Cancer Testing<\/a><\/strong> \u2014 The genomic-testing pillar should be the primary parent for germline testing, genetic counseling, consent, family implications, and variant interpretation. <em>Status: create a focused P19 subpillar and cross-link from P15.<\/em><\/li>\n\n\n\n<li><strong>Multi-Cancer Detection Testing<\/strong> \u2014 Proposed page comparing intended-use populations, cancer-signal detection, tissue-of-origin prediction, diagnostic-resolution pathways, false positives, false negatives, interval cancers, regulatory status, and mortality evidence. <em>Status: create only with scheduled evidence updates; proposed URL: \/blog\/cancer\/multi-cancer-detection-blood-tests\/.<\/em><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Related Individual Tests and Panels<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ordering should begin with the clinical question, not the product list. An individual marker is often preferable when a specific indication exists. A larger panel increases the chance of incidental abnormalities and does not automatically improve cancer detection.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Common Starting Tests<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC with differential and platelets<\/a> \u2014 evaluates blood-cell patterns and may support baseline or treatment-safety monitoring.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">Comprehensive metabolic panel<\/a> \u2014 evaluates kidney, liver, electrolyte, protein, calcium, and glucose patterns; it does not diagnose cancer.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Targeted Tumor Markers<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA, total<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">PSA, free and total<\/a> \u2014 selected prostate screening, risk assessment, diagnostic support, or monitoring contexts.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> \u2014 principally monitoring or selected pelvic-mass evaluation, not average-risk ovarian-cancer screening.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> \u2014 principally baseline and monitoring in selected known cancers, especially colorectal cancer.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP tumor marker<\/a> \u2014 selected liver or germ-cell tumor contexts.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a> \u2014 selected pancreaticobiliary or gastrointestinal cancer monitoring and diagnostic-support contexts.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">Quantitative hCG<\/a> \u2014 pregnancy evaluation and selected germ-cell or trophoblastic tumor contexts; pregnancy status is essential to interpretation.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/lactate-dehydrogenase-test\">LDH<\/a> \u2014 nonspecific tissue-injury marker used in selected hematologic, germ-cell, and other oncology contexts.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Monoclonal-Protein and Plasma-Cell Testing<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/protein-electrophoresis-serum\">Serum protein electrophoresis<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/immunofixation-serum-test\">Serum immunofixation<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/kappa-lambda-light-chains-free-with-ratio-blood-test\">Kappa and lambda free light chains with ratio<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/www.ultalabtests.com\/test\/beta-2-microglobulin-serum\">Beta-2 microglobulin<\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">These tests may help evaluate or monitor monoclonal gammopathies and plasma-cell disorders, but abnormal findings do not establish multiple myeloma without the full diagnostic workup.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Panels Requiring Especially Careful Selection<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Ulta currently lists broad products such as <a href=\"https:\/\/www.ultalabtests.com\/test\/cancer-blood-tests-18-key-lab-tests-used-in-cancer-screening\">Cancer Blood Tests: 18 Key Lab Tests Used in Cancer Screening<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/cancer-screening-women\">Cancer Screening for Women<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/cancer-screening-men\">Cancer Screening for Men<\/a>, and a <a href=\"https:\/\/www.ultalabtests.com\/test\/pancreatic-cancer-tumor-marker-blood-panel\">pancreatic cancer tumor-marker panel<\/a>. Their exact names, components, preparation, and patient-facing claims must be reverified before publication. The word \u201cscreening\u201d in a commercial panel name does not mean that every component is recommended by a guideline for population cancer screening. These products should be presented as collections of selected laboratory measures whose usefulness depends on indication, risk, and professional follow-up\u2014not as tests that diagnose, exclude, or broadly screen for cancer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For a narrower catalog view, see Ulta\u2019s <a href=\"https:\/\/www.ultalabtests.com\/testing\/categories\/cancer-screening\/tumor-marker\">tumor-marker testing category<\/a>. Product availability and ordering eligibility vary by test and jurisdiction.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">How Ulta Lab Tests May Help<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Where a test is available and the customer is eligible, Ulta Lab Tests allows people to review laboratory options and displayed pricing online, complete the ordering process, use a participating collection site, and receive results through an online account. Direct access can support an informed conversation; it does not replace cancer screening guidance, a physical examination, imaging, pathology, genetic counseling, or oncology care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Before ordering, review the product page for the exact specimen, preparation, collection, eligibility, and expected result process. Use <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/direct-access-lab-testing\/\">Direct-Access Lab Testing: How It Works and What to Expect<\/a> to understand ordering, preparation, collection, result delivery, and responsible follow-up.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Questions to Ask a Healthcare Professional<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>What exact question would this blood test answer?<\/li>\n\n\n\n<li>Is the test being used for screening, diagnostic support, a pretreatment baseline, treatment safety, response monitoring, or recurrence surveillance?<\/li>\n\n\n\n<li>Is this marker known to be informative for my specific cancer type and stage?<\/li>\n\n\n\n<li>Could a benign condition, recent procedure, pregnancy, medicine, supplement, smoking, infection, or organ dysfunction affect the result?<\/li>\n\n\n\n<li>Would a guideline-recommended screening test, examination, imaging study, endoscopy, or biopsy be more appropriate?<\/li>\n\n\n\n<li>What would we do after a positive, high, low, or indeterminate result?<\/li>\n\n\n\n<li>What would we do after a normal result if symptoms continue?<\/li>\n\n\n\n<li>Should the result be repeated with the same method or complemented by another test?<\/li>\n\n\n\n<li>For <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, how do my age, family history, ancestry, prostate history, and preferences affect the screening decision?<\/li>\n\n\n\n<li>For an emerging liquid biopsy, is the assay FDA approved or authorized for this exact intended use?<\/li>\n\n\n\n<li>Has the test been shown to improve outcomes, or only to detect a signal earlier?<\/li>\n\n\n\n<li>Could hereditary-cancer evaluation or genetic counseling be appropriate for me or my family?<\/li>\n\n\n\n<li>How will the result be documented and trended over time?<\/li>\n\n\n\n<li>Which symptoms or result changes should prompt faster or urgent evaluation?<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">Frequently Asked Questions<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Can a blood test diagnose cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Usually not by itself. Some blood cancers can produce characteristic blood or marrow findings, and certain molecular assays can support defined decisions, but most solid cancers require imaging and tissue pathology for diagnosis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can normal cancer blood tests rule out cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Many cancers do not release measurable markers, and a marker may remain normal even when cancer is present. Persistent concerning symptoms still require appropriate evaluation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Does an elevated tumor marker mean I have cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Benign disease, inflammation, infection, smoking, pregnancy, organ dysfunction, medicines, procedures, and assay variation can elevate selected markers. The result must be interpreted with its indication, degree and trend, related testing, and clinical findings.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Which tumor markers are used mainly for monitoring?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-19-9\">CA 19-9<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/alpha-fetoprotein-tumor-marker\">AFP<\/a>, <a href=\"https:\/\/www.ultalabtests.com\/test\/hcg-total-quantitative-test\">hCG<\/a>, and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> may be used to establish a baseline or monitor selected known cancers, depending on whether the person\u2019s tumor produces the marker. Their use is cancer- and context-specific.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> a cancer screening test?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a> is used in prostate-cancer screening, but it is not cancer-specific. The decision to screen should consider age, risk, potential benefits and harms, and personal preferences; abnormal results often require repeat testing and additional evaluation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Is <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> recommended to screen everyone for ovarian cancer?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. Routine <a href=\"https:\/\/www.ultalabtests.com\/test\/ca-125\">CA-125<\/a> screening is not recommended for asymptomatic average-risk women because false-positive results and unnecessary procedures can cause harm. High-risk people need a specialized risk and surveillance plan.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Can <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> replace a colonoscopy or stool screening test?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">No. <a href=\"https:\/\/www.ultalabtests.com\/test\/CEA\">CEA<\/a> is not a colorectal-cancer screening test. Established colorectal-screening options are chosen according to age, risk, preference, availability, and current guidance; an abnormal non-colonoscopy screen generally requires colonoscopy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What is the difference between <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">free PSA<\/a>?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">Total PSA<\/a> includes bound and unbound <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>. <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">Free PSA<\/a> measures the unbound portion; <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-free-and-total\">percent-free PSA<\/a> may add risk context in selected people with an abnormal <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">total PSA<\/a>. It does not confirm or exclude cancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Why are <a href=\"https:\/\/www.ultalabtests.com\/test\/complete-blood-count-with-differential-and-platelets-cbc-test\">CBC<\/a> and <a href=\"https:\/\/www.ultalabtests.com\/test\/comprehensive-metabolic-panel-test-cmp\">CMP<\/a> ordered in cancer care?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">They help assess blood cells, kidney and liver function, electrolytes, calcium, proteins, and treatment safety. They can reveal abnormalities requiring attention but usually do not identify the cancer type or location.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What is a liquid biopsy?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">It is a blood-based assay that analyzes tumor-derived material or other cancer-associated signals. Some assays are FDA authorized for treatment selection or specific screening uses; others are used for residual-disease assessment, surveillance, or research. Evidence is assay- and indication-specific.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Are multi-cancer early-detection tests proven to save lives?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">As of August 7, 2026, broad population evidence has not established that available multi-cancer detection testing reduces overall or cancer-specific mortality. A positive signal requires diagnostic resolution, while a negative result does not replace recommended screening.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What happens after a positive multi-cancer signal?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The next steps depend on the predicted tissue of origin and may include examination, imaging, endoscopy, targeted laboratory tests, and biopsy. Diagnostic resolution can take multiple procedures, and some signals do not yield a cancer diagnosis.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">When is hereditary cancer testing different from a tumor marker?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Hereditary testing looks for germline variants that may affect inherited risk and relatives. Tumor-marker testing usually measures a circulating protein or disease signal. Tumor genomic testing examines acquired changes in cancer cells and may guide treatment. These tests answer different questions.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Should I order the largest cancer panel available?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Not automatically. Larger panels can generate incidental abnormalities, false reassurance, anxiety, and follow-up procedures without improving screening. A focused test linked to a defined clinical question is usually easier to interpret.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion: Use Cancer Blood Tests for the Right Question<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Cancer blood tests<\/strong> include routine blood counts and chemistry testing, selected tumor markers, monoclonal-protein studies, and increasingly specialized molecular assays. Focused testing can support risk discussions, diagnostic evaluation, treatment safety, response assessment, and recurrence monitoring. It cannot by itself diagnose most cancers, rule cancer out, or replace established screening, imaging, endoscopy, pathology, and specialist evaluation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The safest approach begins with the purpose of testing, weighs false-positive and false-negative consequences, and interprets each result in the context of symptoms, risk, preparation, method, related findings, and trends. Use <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/how-to-read-lab-results\/\">the guide to understanding laboratory results<\/a> for ranges, flags, variation, and trends; review <a href=\"https:\/\/www.ultalabtests.com\/blog\/lab-testing-knowledge-center\/direct-access-lab-testing\/\">the direct-access testing process<\/a> before ordering; and explore the focused subpillars above for <a href=\"https:\/\/www.ultalabtests.com\/test\/psa-total\">PSA<\/a>, symptom-specific evaluation, hereditary risk, and emerging multi-cancer detection.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Primary References<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.cancer.gov\/about-cancer\/diagnosis-staging\/diagnosis\/tumor-markers-fact-sheet\">Tumor Markers<\/a>. National Cancer Institute. Updated December 7, 2023; accessed August 7, 2026. Supports definitions, common uses, limitations, and the need for imaging or biopsy.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/about-cancer\/diagnosis-staging\/diagnosis\/tumor-markers-list\">Tumor Marker Tests in Common Use<\/a>. National Cancer Institute. Accessed August 7, 2026. Supports cancer associations and intended uses for AFP, beta-hCG, CA 19-9, CA-125, CEA, PSA, and related markers.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/types\/prostate\/psa-fact-sheet\">Prostate-Specific Antigen Test<\/a>. National Cancer Institute. Updated January 31, 2025. Supports PSA screening, benign causes of elevation, repeat testing, and follow-up limitations.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/prostate-cancer-screening\">Prostate Cancer: Screening<\/a>. U.S. Preventive Services Task Force. June 2018; current page accessed August 7, 2026. Supports shared decision-making and screening-harm context.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/ovarian-cancer-screening\">Ovarian Cancer: Screening<\/a>. U.S. Preventive Services Task Force. February 13, 2018; current page accessed August 7, 2026. Supports the recommendation against screening asymptomatic average-risk women with CA-125 or transvaginal ultrasound.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/ca-125-blood-test-ovarian-cancer\/\">CA-125 Blood Test (Ovarian Cancer)<\/a>. MedlinePlus, National Library of Medicine. Updated July 2, 2025. Supports monitoring use, benign causes of elevation, and diagnostic limitations.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/cea-test\/\">MedlinePlus guide to CEA testing<\/a>. National Library of Medicine. Updated July 27, 2026; accessed August 7, 2026. Supports monitoring use and the statement that CEA is not a stand-alone screening or diagnostic test.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/alpha-fetoprotein-afp-tumor-marker-test\/\">Alpha-Fetoprotein (AFP) Tumor Marker Test<\/a>. MedlinePlus, National Library of Medicine. Updated June 30, 2026. Supports selected liver and germ-cell tumor uses and noncancer causes of elevation.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/ca-19-9-blood-test-pancreatic-cancer\/\">CA 19-9 Blood Test<\/a>. MedlinePlus, National Library of Medicine. Updated January 20, 2026. Supports pancreaticobiliary monitoring, benign elevations, and screening limitations.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/lactate-dehydrogenase-ldh-test\/\">Lactate Dehydrogenase (LDH) Test<\/a>. MedlinePlus, National Library of Medicine. Accessed August 7, 2026. Supports LDH as a nonspecific tissue-damage marker.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/free-light-chains\/\">Free Light Chains<\/a>. MedlinePlus, National Library of Medicine. Updated April 10, 2024. Supports plasma-cell-disorder evaluation and kidney-function limitations.<\/li>\n\n\n\n<li><a href=\"https:\/\/prevention.cancer.gov\/research-areas\/networks-consortia-programs\/csrn\/q-a-about-mcd-tests\">Questions and Answers About Multi-Cancer Detection Tests<\/a>. National Cancer Institute. Accessed August 7, 2026. Supports distinctions among cancer-signal detection, diagnostic resolution, false positives, false negatives, and unproven mortality benefit.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/list-fda-authorized-companion-diagnostic-devices-in-vitro-and-imaging-tools\">List of FDA-Authorized Companion Diagnostic Devices<\/a>. U.S. Food and Drug Administration. Accessed August 7, 2026. Supports established plasma-based molecular testing for selected treatment decisions.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.fda.gov\/medical-devices\/recently-approved-devices\/shield-p230009\">Shield\u2014P230009<\/a>. U.S. Food and Drug Administration. July 26, 2024. Supports the approved intended use and limitations of a blood-based colorectal screening test for average-risk adults age 45 or older.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-adjuvant-treatment-muscle-invasive-bladder-cancer-patients-molecular\">FDA Approves Atezolizumab for Adjuvant Treatment of Muscle-Invasive Bladder Cancer in Patients with Molecular Residual Disease<\/a>. U.S. Food and Drug Administration. May 15, 2026. Supports one defined ctDNA-MRD companion-diagnostic use.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.org\/health-care-professionals\/american-cancer-society-prevention-early-detection-guidelines\/colorectal-cancer-screening-guidelines.html\">Colorectal Cancer Screening Guidelines<\/a>. American Cancer Society. Accessed August 7, 2026. Supports current colorectal-screening options, placement of blood-based testing, and follow-up colonoscopy.<\/li>\n\n\n\n<li><a href=\"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.70083\">Colorectal Cancer Screening for Average-Risk Adults: 2026 Guideline Update<\/a>. CA: A Cancer Journal for Clinicians. 2026. Supports blood-based testing as an option for people who decline or do not complete preferred stool-based or visual screening.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/breast-cancer-screening\">Breast Cancer: Screening<\/a>. U.S. Preventive Services Task Force. April 30, 2024. Supports mammography-based population screening rather than tumor-marker screening.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/colorectal-cancer-screening\">Colorectal Cancer: Screening<\/a>. U.S. Preventive Services Task Force. May 18, 2021; current page accessed August 7, 2026. Supports established stool and visual screening strategies.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/lung-cancer-screening\">Lung Cancer: Screening<\/a>. U.S. Preventive Services Task Force. March 9, 2021; current page accessed August 7, 2026. Supports low-dose CT for eligible high-risk adults rather than a conventional blood marker.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/cervical-cancer-screening\">Cervical Cancer: Screening<\/a>. U.S. Preventive Services Task Force. August 21, 2018; current page accessed August 7, 2026. Supports cervical screening with HPV testing and\/or cytology rather than tumor markers. Reverify at publication because an update is in progress.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.uspreventiveservicestaskforce.org\/uspstf\/recommendation\/pancreatic-cancer-screening\">Pancreatic Cancer: Screening<\/a>. U.S. Preventive Services Task Force. August 6, 2019; current page accessed August 7, 2026. Supports the recommendation against population screening of asymptomatic average-risk adults.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.cancer.gov\/about-cancer\/causes-prevention\/genetics\/genetic-testing-fact-sheet\">Genetic Testing for Inherited Cancer Risk<\/a>. National Cancer Institute. Accessed August 7, 2026. Supports counseling, informed consent, germline testing, and family implications.<\/li>\n\n\n\n<li><a href=\"https:\/\/grail.com\/press-releases\/grail-submits-fda-premarket-approval-application-for-the-galleri-multi-cancer-early-detection-test\/\">GRAIL Submits FDA Premarket Approval Application for the Galleri Multi-Cancer Early Detection Test<\/a>. GRAIL. January 29, 2026; accessed August 7, 2026. Manufacturer source used only to document regulatory-submission status, not clinical effectiveness.<\/li>\n\n\n\n<li><a href=\"https:\/\/www.asco.org\/about-asco\/press-center\/galleri-early-detection-shift-timing-cancer-detection\">Galleri Early Detection Test May Shift Timing of Cancer Detection<\/a>. American Society of Clinical Oncology. May 30, 2026; accessed August 7, 2026. Supports reporting that the NHS-Galleri trial\u2019s primary endpoint was not met; full peer-reviewed publication and regulatory review should be tracked.<\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37805216\/\">PATHFINDER: A Prospective Cohort Study of Multi-Cancer Early Detection<\/a>. The Lancet. 2023. PubMed record accessed August 7, 2026. Supports feasibility, diagnostic-resolution, and false-positive context; it does not establish mortality benefit.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/complete-blood-count-cbc\/\">Complete Blood Count (CBC)<\/a>. MedlinePlus, National Library of Medicine. Updated October 15, 2024. Supports CBC components, general interpretation, and nonspecific abnormal patterns.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/comprehensive-metabolic-panel-cmp\/\">Comprehensive Metabolic Panel (CMP)<\/a>. MedlinePlus, National Library of Medicine. Updated December 4, 2023. Supports CMP contents and organ-function context.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/protein-electrophoresis-by-immunofixation-blood-test\/\">Protein Electrophoresis by Immunofixation Blood Test<\/a>. MedlinePlus, National Library of Medicine. Updated May 1, 2024. Supports protein separation, immunofixation, and the need for broader interpretation.<\/li>\n\n\n\n<li><a href=\"https:\/\/medlineplus.gov\/lab-tests\/beta-2-microglobulin-b2m-tumor-marker-test\/\">Beta-2 Microglobulin Tumor Marker Test<\/a>. MedlinePlus, National Library of Medicine. Updated December 30, 2025. Supports monitoring and prognostic uses, noncancer elevations, and the limitation that B2M does not diagnose cancer.<\/li>\n<\/ol>\n\n\n\n<h2 id=\"h-editorial-disclosure-authorship-and-medical-note\" class=\"wp-block-heading\"><strong>Editorial Disclosure, Authorship, and Medical Note<\/strong><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ulta Lab Tests provides direct-access laboratory testing. Product links are included when they match the educational topic; purchasing a test is not a substitute for diagnosis, treatment, or urgent medical care.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Written by:<\/strong> John R. | <strong>Originally published:<\/strong> August 1, 2026 | <strong>Last updated:<\/strong> August 7, 2026<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Medical note:<\/strong> This guide is educational. A clinician should select and interpret testing in the context of symptoms, diagnoses, medications, pregnancy status, nutrition, hydration, and prior results. Do not start, stop, or change a prescription based on this article or one laboratory result.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cancer blood tests include routine blood counts and chemistry tests, selected protein tumor markers, and specialized genomic assays. They may reveal blood-cell or organ-function changes, support a diagnosis alongside imaging and pathology, establish a pretreatment [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[74,281,63,62,69,64,75,70,4981,4980,210,66,72,241,67,73,203],"tags":[5539,5538,5543,5558,5547,5553,5549,1357,5582,5534,5537,5541,5586,5573,5574,5535,5545,1367,2662,5575,5542,5533,5531,1470,5550,5578,2085,5536,1337,2080,5587,2436,5546,5551,5540,5563,2700,5569,5552,5568,5579,5577,5565,5562,5570,5572,5548,5571,5580,5584,5560,5585,5564,5544,5583,5556,5529,5530,5555,5554,2692,5561,3562,1507,1505,5432,5559,5567,5576,5557,2694,5566,5532,5581,1349],"class_list":["post-2994","post","type-post","status-publish","format-standard","hentry","category-breast-cancer","category-breast-health","category-all-cancer","category-cancer","category-cancer-and-tumor-markers-men","category-cancer-and-tumor-markers-women","category-cervical-cancer","category-colon-and-rectal-cancer","category-lab-testing-knowledge-center-lab-testing-knowledge-center","category-lab-testing-knowledge-center","category-mens-health","category-ovarian-cancer","category-pancreatic-cancer","category-prostate","category-prostate-cancer","category-testicular-cancer","category-womens-health","tag-abnormal-cancer-marker","tag-afp-test","tag-alpha-fetoprotein","tag-beta-2-microglobulin","tag-blood-tests-for-cancer","tag-ca-19-9-test","tag-ca-125-test-2","tag-cancer-biomarkers","tag-cancer-blood-test-results","tag-cancer-blood-tests","tag-cancer-diagnostic-support","tag-cancer-follow-up-testing","tag-cancer-genomics","tag-cancer-lab-test-preparation","tag-cancer-marker-interpretation","tag-cancer-monitoring-tests","tag-cancer-recurrence-monitoring","tag-cancer-risk-assessment","tag-cancer-screening-blood-tests","tag-cancer-screening-guidelines","tag-cancer-screening-limitations","tag-cancer-treatment-monitoring","tag-carcinoembryonic-antigen","tag-cbc-test","tag-cea-test","tag-circulating-tumor-dna","tag-cmp-test","tag-colorectal-cancer-monitoring","tag-complete-blood-count","tag-comprehensive-metabolic-panel","tag-ctdna","tag-direct-access-lab-testing-2","tag-elevated-tumor-marker","tag-false-negative-tumor-marker","tag-false-positive-tumor-marker","tag-free-light-chains","tag-free-psa","tag-genetic-cancer-risk","tag-germ-cell-tumor-markers","tag-hcg-tumor-marker","tag-hereditary-cancer-testing","tag-imaging-and-biopsy","tag-kappa-lambda-ratio","tag-lactate-dehydrogenase","tag-ldh-test","tag-liquid-biopsy","tag-liver-cancer-tumor-marker","tag-lymphoma-monitoring","tag-mced-tests","tag-molecular-residual-disease","tag-monoclonal-gammopathy","tag-multi-cancer-early-detection","tag-multiple-myeloma-testing","tag-noncancer-causes-of-elevated-tumor-markers","tag-oncology-lab-tests","tag-organ-function-testing","tag-ovarian-cancer-monitoring","tag-ovarian-cancer-tumor-marker","tag-pancreatic-cancer-monitoring","tag-pancreatic-cancer-tumor-marker","tag-percent-free-psa","tag-plasma-cell-disorder-testing","tag-prostate-cancer-monitoring","tag-prostate-cancer-screening","tag-psa-test","tag-quantitative-hcg","tag-serum-immunofixation","tag-serum-protein-electrophoresis","tag-specialist-directed-testing","tag-spep-test","tag-total-psa","tag-treatment-safety-testing","tag-tumor-marker-tests","tag-tumor-marker-trends","tag-tumor-markers"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.1 (Yoast SEO v28.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps | Ulta Lab Tests<\/title>\n<meta name=\"description\" content=\"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps\" \/>\n<meta property=\"og:description\" content=\"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/\" \/>\n<meta property=\"og:site_name\" content=\"Ulta Lab Tests\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/ultalabtests\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-02T02:22:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-07T21:33:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&quality=100&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"405\" \/>\n\t<meta property=\"og:image:height\" content=\"79\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"John R\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"John R\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"44 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps | Ulta Lab Tests","description":"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","og_locale":"en_US","og_type":"article","og_title":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps","og_description":"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.","og_url":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","og_site_name":"Ulta Lab Tests","article_publisher":"https:\/\/facebook.com\/ultalabtests","article_published_time":"2026-08-02T02:22:41+00:00","article_modified_time":"2026-08-07T21:33:07+00:00","og_image":[{"width":405,"height":79,"url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&quality=100&ssl=1","type":"image\/png"}],"author":"John R","twitter_card":"summary_large_image","twitter_misc":{"Written by":"John R","Est. reading time":"44 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#article","isPartOf":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/"},"author":{"name":"John R","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/person\/e9af1f4fe34b68909911dc95c313ed6a"},"headline":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps","datePublished":"2026-08-02T02:22:41+00:00","dateModified":"2026-08-07T21:33:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/"},"wordCount":9922,"commentCount":0,"publisher":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#organization"},"keywords":["abnormal cancer marker","AFP test","alpha-fetoprotein","beta-2 microglobulin","blood tests for cancer","CA 19-9 test","CA-125 test","cancer biomarkers","cancer blood test results","cancer blood tests","cancer diagnostic support","cancer follow-up testing","cancer genomics","cancer lab test preparation","cancer marker interpretation","cancer monitoring tests","cancer recurrence monitoring","cancer risk assessment","cancer screening blood tests","cancer screening guidelines","cancer screening limitations","cancer treatment monitoring","carcinoembryonic antigen","cbc test","CEA test","circulating tumor DNA","CMP test","colorectal cancer monitoring","complete blood count","Comprehensive Metabolic Panel","ctDNA","Direct-Access Lab Testing","elevated tumor marker","false-negative tumor marker","false-positive tumor marker","free light chains","free PSA","genetic cancer risk","germ-cell tumor markers","hCG tumor marker","hereditary cancer testing","imaging and biopsy","kappa lambda ratio","lactate dehydrogenase","LDH test","liquid biopsy","liver cancer tumor marker","lymphoma monitoring","MCED tests","molecular residual disease","monoclonal gammopathy","multi-cancer early detection","multiple myeloma testing","noncancer causes of elevated tumor markers","oncology lab tests","organ function testing","ovarian cancer monitoring","ovarian cancer tumor marker","pancreatic cancer monitoring","pancreatic cancer tumor marker","percent free PSA","plasma cell disorder testing","prostate cancer monitoring","Prostate cancer screening","PSA test","quantitative hCG","serum immunofixation","serum protein electrophoresis","specialist-directed testing","SPEP test","total PSA","treatment safety testing","tumor marker tests","tumor marker trends","tumor markers"],"articleSection":["Breast Cancer","Breast Health","Cancer","Cancer","Cancer and Tumor Markers - Men","Cancer and Tumor Markers - Women","Cervical Cancer","Colon and Rectal Cancer","Lab Testing Knowledge Center","Lab Testing Knowledge Center","Men's Health","Ovarian Cancer","Pancreatic Cancer","Prostate","Prostate Cancer","Testicular Cancer","Women's Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","url":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/","name":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps | Ulta Lab Tests","isPartOf":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#website"},"datePublished":"2026-08-02T02:22:41+00:00","dateModified":"2026-08-07T21:33:07+00:00","description":"Cancer blood tests and tumor marker tests explained: learn why cancer screening blood tests have limits and how results guide follow-up care.","breadcrumb":{"@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ultalabtests.com\/blog\/cancer\/cancer-blood-tests-and-tumor-markers-uses-limitations-and-follow-upcancer-blood-tests-tumor-markers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Ulta Lab Tests","item":"https:\/\/www.ultalabtests.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Cancer","item":"https:\/\/www.ultalabtests.com\/blog\/category\/cancer\/"},{"@type":"ListItem","position":3,"name":"Cancer Blood Tests and Tumor Markers: Uses, Limits, and Next Steps"}]},{"@type":"WebSite","@id":"https:\/\/www.ultalabtests.com\/blog\/#website","url":"https:\/\/www.ultalabtests.com\/blog\/","name":"Ulta Lab Tests","description":"You Order the Test. We&#039;ll Do the Rest!","publisher":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ultalabtests.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ultalabtests.com\/blog\/#organization","name":"Ulta Lab Tests","url":"https:\/\/www.ultalabtests.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.ultalabtests.com\/blog\/wp-content\/uploads\/2023\/02\/logo.png?fit=405%2C79&ssl=1","width":405,"height":79,"caption":"Ulta Lab Tests"},"image":{"@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/ultalabtests","http:\/\/www.linkedin.com\/company\/3335617"]},{"@type":"Person","@id":"https:\/\/www.ultalabtests.com\/blog\/#\/schema\/person\/e9af1f4fe34b68909911dc95c313ed6a","name":"John R","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d48f9c8356694121fd9e2793e13d6aa6855e5df11f9b14f7a872b4ea554581fb?s=96&d=mm&r=g","caption":"John R"}}]}},"featured_image_src":null,"featured_image_src_square":null,"author_info":{"display_name":"John R","author_link":"https:\/\/www.ultalabtests.com\/blog\/author\/johnroehmultalabtests-com\/"},"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts\/2994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/comments?post=2994"}],"version-history":[{"count":0,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/posts\/2994\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/media?parent=2994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/categories?post=2994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ultalabtests.com\/blog\/wp-json\/wp\/v2\/tags?post=2994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}